Scholars Central

Conference abstractPublished 30 Aug 2022

Suppression of the Osteopontin-Dependent TH1 Response is a Key Mechanism in Cytokine Storms

Authors: Georg F. Weber

Professor, University of Cincinnati Academic Health Center, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The severe complication of a cytokine release syndrome can arise in various disease states. Often, those are caused by bacterial or viral infections, such as those with SARS-CoV-2, the virus that underlies the COVID-19 pandemic. The cytokine storm disease manifestation represents an inefficient, even harmful immune response, which is associated with a release of a wide spectrum of chemokine’s. Whereas a cellular (type I, TH1) immune activation pattern is efficacious for clearing viral infections, we noted an unexpected type I deficit in the cytokine profiles generated by cytokine storms of all known etiologies. Several trigger agents, including bacterial LPS (lipopolysaccharide), the antibody anti-CD3 and various preparations of the viral Spike Glycoprotein (the exposed SARS-CoV-2 surface molecule), were each sufficient to induce IL-6 and various chemokine’s in mice. Not only did they fail to up regulate the TH1 inducer cytokine OPN (Osteopontin), but the pathophysiologic triggers actually inhibited the PMA-induced OPN secretion from monocytic cells. The therapeutic administration of OPN to mice at least partially reversed the chemokine elevation. This was more pronounced in a mouse strain that displays a TH1 bias.Our data indicate that the suppression of OPN by Spike Glycoprotein (from SARS-CoV-2) or by LPS (from various bacterial sources) represents an immune evasion mechanism employed by the pathogens of origin. This down regulation of a key mediator for cellular immunity prompts a dysfunctional inflammatory response that leads to a vicious cycle of amplification, finally resulting in a cytokine storm. Administration of the cytokine OPN may be a candidate for treating cytokine release syndromes, in particular when they are triggered by viral causes. The immunogenetic makeup of the patients is an important variable. A pharmacogenetic predisposition toward TH2 (humoral) responses may require higher dosing to reach efficacy. In those patients, who favour TH1 (cellular) responses, an OPN-mediated amelioration of the cytokine profile away from the storm will likely not need to be very strong. Furthermore, it is very probable that older patients, who experience hypo-responsiveness of their macrophages, would need elevated OPN dosing to overcome the adverse manifestations of cytokine storms.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Clinical and Cellular Immunology
  • SubjectImmunology & Microbiology
  • BylineArticles whose byline prints “Georg F. Weber”